Clinical Significance of Dysadherin Expression in Gastric Cancer Patients

Yutaka Shimada, Seiji Yamasaki, Yosuke Hashimoto, Tetsuo Ito, Jun Ichiro Kawamura, Toshiya Soma, Yoshinori Ino, Yukihiro Nakanishi, Michiie Sakamoto, Setsuo Hirohashi, Masayuki Imamura

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: Dysadherin, a cancer-associated cell membrane glycoprotein, has been reported to down-regulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in gastric cancer, we examined dysadherin and E-cadherin expression in gastric cancer patients. Experimental Design: Dysadherin and E-cadherin expression were evaluated in 276 gastric cancer patients by immunohistochemistry, and the results were compared with the clinicopathological findings of the subjects. Results: Dysadherin was not expressed in normal gastric epithelium. Both dysadherin and E-cadherin were localized to the cell membrane. Dysadherin expression was sometimes largely localized to infiltrating tumor cells or cells dissociating. Ninety gastric cancer patients (32.6%) were positive for dysadherin, and 151 patients (54.7%) showed preservation of E-cadherin expression. Expression of dysadherin was associated with moderately differentiated carcinoma and hematogenous metastasis, whereas reduced expression of E-cadherin showed an association with poorly differentiated carcinoma and peritoneal dissemination. As a result, dysadherin positivity and reduced E-cadherin expression were associated with a poor prognosis. In addition, patients with both dysadherin positivity and reduced E-cadherin had the worst prognosis. Multivariate analysis revealed that reduced E-cadherin expression was an independent prognostic factor, but dysadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis and the mode of metastasis in gastric cancer patients. Patients with dysadherin positivity have a higher risk of hematogenous metastasis, whereas patients with reduced E-cadherin expression have an increased risk of peritoneal dissemination.

Original languageEnglish
Pages (from-to)2818-2823
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number8
DOIs
Publication statusPublished - 2004 Apr 15

Fingerprint

Cadherins
Stomach Neoplasms
Neoplasm Metastasis
Cell Membrane
Carcinoma
Membrane Glycoproteins
Neoplasms
Stomach
Research Design
Down-Regulation
Multivariate Analysis
Epithelium
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shimada, Y., Yamasaki, S., Hashimoto, Y., Ito, T., Kawamura, J. I., Soma, T., ... Imamura, M. (2004). Clinical Significance of Dysadherin Expression in Gastric Cancer Patients. Clinical Cancer Research, 10(8), 2818-2823. https://doi.org/10.1158/1078-0432.CCR-0633-03

Clinical Significance of Dysadherin Expression in Gastric Cancer Patients. / Shimada, Yutaka; Yamasaki, Seiji; Hashimoto, Yosuke; Ito, Tetsuo; Kawamura, Jun Ichiro; Soma, Toshiya; Ino, Yoshinori; Nakanishi, Yukihiro; Sakamoto, Michiie; Hirohashi, Setsuo; Imamura, Masayuki.

In: Clinical Cancer Research, Vol. 10, No. 8, 15.04.2004, p. 2818-2823.

Research output: Contribution to journalArticle

Shimada, Y, Yamasaki, S, Hashimoto, Y, Ito, T, Kawamura, JI, Soma, T, Ino, Y, Nakanishi, Y, Sakamoto, M, Hirohashi, S & Imamura, M 2004, 'Clinical Significance of Dysadherin Expression in Gastric Cancer Patients', Clinical Cancer Research, vol. 10, no. 8, pp. 2818-2823. https://doi.org/10.1158/1078-0432.CCR-0633-03
Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura JI, Soma T et al. Clinical Significance of Dysadherin Expression in Gastric Cancer Patients. Clinical Cancer Research. 2004 Apr 15;10(8):2818-2823. https://doi.org/10.1158/1078-0432.CCR-0633-03
Shimada, Yutaka ; Yamasaki, Seiji ; Hashimoto, Yosuke ; Ito, Tetsuo ; Kawamura, Jun Ichiro ; Soma, Toshiya ; Ino, Yoshinori ; Nakanishi, Yukihiro ; Sakamoto, Michiie ; Hirohashi, Setsuo ; Imamura, Masayuki. / Clinical Significance of Dysadherin Expression in Gastric Cancer Patients. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 8. pp. 2818-2823.
@article{2c6c5ee3688d49db84e3f43a17e0a1f7,
title = "Clinical Significance of Dysadherin Expression in Gastric Cancer Patients",
abstract = "Purpose: Dysadherin, a cancer-associated cell membrane glycoprotein, has been reported to down-regulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in gastric cancer, we examined dysadherin and E-cadherin expression in gastric cancer patients. Experimental Design: Dysadherin and E-cadherin expression were evaluated in 276 gastric cancer patients by immunohistochemistry, and the results were compared with the clinicopathological findings of the subjects. Results: Dysadherin was not expressed in normal gastric epithelium. Both dysadherin and E-cadherin were localized to the cell membrane. Dysadherin expression was sometimes largely localized to infiltrating tumor cells or cells dissociating. Ninety gastric cancer patients (32.6{\%}) were positive for dysadherin, and 151 patients (54.7{\%}) showed preservation of E-cadherin expression. Expression of dysadherin was associated with moderately differentiated carcinoma and hematogenous metastasis, whereas reduced expression of E-cadherin showed an association with poorly differentiated carcinoma and peritoneal dissemination. As a result, dysadherin positivity and reduced E-cadherin expression were associated with a poor prognosis. In addition, patients with both dysadherin positivity and reduced E-cadherin had the worst prognosis. Multivariate analysis revealed that reduced E-cadherin expression was an independent prognostic factor, but dysadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis and the mode of metastasis in gastric cancer patients. Patients with dysadherin positivity have a higher risk of hematogenous metastasis, whereas patients with reduced E-cadherin expression have an increased risk of peritoneal dissemination.",
author = "Yutaka Shimada and Seiji Yamasaki and Yosuke Hashimoto and Tetsuo Ito and Kawamura, {Jun Ichiro} and Toshiya Soma and Yoshinori Ino and Yukihiro Nakanishi and Michiie Sakamoto and Setsuo Hirohashi and Masayuki Imamura",
year = "2004",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-0633-03",
language = "English",
volume = "10",
pages = "2818--2823",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Clinical Significance of Dysadherin Expression in Gastric Cancer Patients

AU - Shimada, Yutaka

AU - Yamasaki, Seiji

AU - Hashimoto, Yosuke

AU - Ito, Tetsuo

AU - Kawamura, Jun Ichiro

AU - Soma, Toshiya

AU - Ino, Yoshinori

AU - Nakanishi, Yukihiro

AU - Sakamoto, Michiie

AU - Hirohashi, Setsuo

AU - Imamura, Masayuki

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Purpose: Dysadherin, a cancer-associated cell membrane glycoprotein, has been reported to down-regulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in gastric cancer, we examined dysadherin and E-cadherin expression in gastric cancer patients. Experimental Design: Dysadherin and E-cadherin expression were evaluated in 276 gastric cancer patients by immunohistochemistry, and the results were compared with the clinicopathological findings of the subjects. Results: Dysadherin was not expressed in normal gastric epithelium. Both dysadherin and E-cadherin were localized to the cell membrane. Dysadherin expression was sometimes largely localized to infiltrating tumor cells or cells dissociating. Ninety gastric cancer patients (32.6%) were positive for dysadherin, and 151 patients (54.7%) showed preservation of E-cadherin expression. Expression of dysadherin was associated with moderately differentiated carcinoma and hematogenous metastasis, whereas reduced expression of E-cadherin showed an association with poorly differentiated carcinoma and peritoneal dissemination. As a result, dysadherin positivity and reduced E-cadherin expression were associated with a poor prognosis. In addition, patients with both dysadherin positivity and reduced E-cadherin had the worst prognosis. Multivariate analysis revealed that reduced E-cadherin expression was an independent prognostic factor, but dysadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis and the mode of metastasis in gastric cancer patients. Patients with dysadherin positivity have a higher risk of hematogenous metastasis, whereas patients with reduced E-cadherin expression have an increased risk of peritoneal dissemination.

AB - Purpose: Dysadherin, a cancer-associated cell membrane glycoprotein, has been reported to down-regulate E-cadherin expression and promote metastasis. To evaluate the role of dysadherin in gastric cancer, we examined dysadherin and E-cadherin expression in gastric cancer patients. Experimental Design: Dysadherin and E-cadherin expression were evaluated in 276 gastric cancer patients by immunohistochemistry, and the results were compared with the clinicopathological findings of the subjects. Results: Dysadherin was not expressed in normal gastric epithelium. Both dysadherin and E-cadherin were localized to the cell membrane. Dysadherin expression was sometimes largely localized to infiltrating tumor cells or cells dissociating. Ninety gastric cancer patients (32.6%) were positive for dysadherin, and 151 patients (54.7%) showed preservation of E-cadherin expression. Expression of dysadherin was associated with moderately differentiated carcinoma and hematogenous metastasis, whereas reduced expression of E-cadherin showed an association with poorly differentiated carcinoma and peritoneal dissemination. As a result, dysadherin positivity and reduced E-cadherin expression were associated with a poor prognosis. In addition, patients with both dysadherin positivity and reduced E-cadherin had the worst prognosis. Multivariate analysis revealed that reduced E-cadherin expression was an independent prognostic factor, but dysadherin expression was not. Conclusion: Combined analysis of dysadherin and E-cadherin expression may help to predict the prognosis and the mode of metastasis in gastric cancer patients. Patients with dysadherin positivity have a higher risk of hematogenous metastasis, whereas patients with reduced E-cadherin expression have an increased risk of peritoneal dissemination.

UR - http://www.scopus.com/inward/record.url?scp=11144354824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354824&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0633-03

DO - 10.1158/1078-0432.CCR-0633-03

M3 - Article

C2 - 15102690

AN - SCOPUS:11144354824

VL - 10

SP - 2818

EP - 2823

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -